These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21650138)

  • 1. Optimizing patent strategies. Maintain a competitive edge by creating a strategic patent portfolio.
    Dykeman DJ
    Health Manag Technol; 2011 May; 32(5):26. PubMed ID: 21650138
    [No Abstract]   [Full Text] [Related]  

  • 2. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 3. US Patent Office strategic plan may penalize biotechs.
    Robertson D
    Nat Biotechnol; 2003 Apr; 21(4):345-6. PubMed ID: 12665807
    [No Abstract]   [Full Text] [Related]  

  • 4. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 6. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 7. If it's regulated like a duck ... uncertainties in implementing the patent exceptions of the Drug Price Competition and Patent Term Restoration Act.
    Bloch DJ
    Food Drug Law J; 1999; 54(1):111-26. PubMed ID: 11758554
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech industry considers foreign competition measure.
    Margolis RE
    Healthspan; 1990 Nov; 7(10):19-20. PubMed ID: 10107734
    [No Abstract]   [Full Text] [Related]  

  • 9. Getting the most out of your IP--patent management along its life cycle.
    Bader MA; Gassmann O; Ziegler N; Ruether F
    Drug Discov Today; 2012 Apr; 17(7-8):281-4. PubMed ID: 22079191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipitor kicks off onslaught of drug patent conversions.
    Reinke T
    Manag Care; 2011 Apr; 20(4):14-6. PubMed ID: 21553681
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Patent protection in modern medical technology].
    Bosch M
    Biomed Tech (Berl); 2002; 47 Suppl 1 Pt 2():686-7. PubMed ID: 12465274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Color as a trademark under the Lanham Act: confusion in the circuits and the need for uniformity.
    Carraway JC
    Law Contemp Probl; 1994; 57(4):243-79. PubMed ID: 10140661
    [No Abstract]   [Full Text] [Related]  

  • 18. Patent protection for Aspergillus-related inventions.
    Jong SC; Birmingham JM
    Biotechnology; 1992; 23():297-311. PubMed ID: 1504603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
    Leary TB
    J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian biotechnology start-ups, 1991-1997: the role of incumbents' patents and strategic alliances in controlling competition.
    Calabrese T; Baum JA; Silverman BS
    Soc Sci Res; 2000 Dec; 29(4):503-34. PubMed ID: 11640233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.